ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
NCT03671889
This study is recruiting at 6 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alzheimer Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 50 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- InSightec
- Last updated on ClinicalTrials.gov
- January 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 6
- Delray Medical Center & Florida Atlantic University · Delray Beach, FL
- Broward Health Medical Center & The University of Florida · Fort Lauderdale, FL
- University of Florida Health Shands · Gainesville, FL
- Baptist Health South Florida & Florida International University · Miami, FL
- Advent Health · Orlando, FL
- Tampa General Hospital · Tampa, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.